ProCE Banner Activity

CE / CME

Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy

Multimedia
In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses treatment considerations for a patient with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Pharmacists : 0.25 contact {hour} ({0.025} CEUs)

Physicians : maximum of 0.25 AMA PRA Category 1 {Credit}

Registered Nurses: 0.25 Nursing contact {hour}

Released: October 14, 2020

Expiration: October 13, 2021

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with chronic lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed chronic lymphocytic leukemia
  • Evaluate promising investigational agents and novel combination regimens in chronic lymphocytic leukemia, including efficacy, unique toxicities, and other practical management considerations
  • Describe the role of measurable residual disease assessment in chronic lymphocytic leukemia care

Program Director Disclosure

Program Director

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from Acerta, AbbVie, Astra Zeneca, BeiGene, Janssen, Pharmacyclics, Genentech, Pfizer, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from Acerta, AbbVie, Astra Zeneca, BeiGene, Janssen, Pharmacyclics, Genentech, Pfizer, and TG Therapeutics.

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has served on advisory boards for AbbVie, BeiGene, Celgene, Kite, and Novartis, and received consulting fees from AstraZeneca, Incyte, and Morphosys.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.25 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.25 contact hours (0.025 CEU). Universal program number is as follows: 0230-9999-20-031-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Disclosure of Unlabeled Use

USF Health OCPD staff have no relevant conflicts of interest to report.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 14, 2020, through October 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with chronic lymphocytic leukemia.